This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Review

. 2004;9(4):357-60.

doi: 10.1634/theoncologist.9-4-357.

Molecularly targeted therapy: have the floodgates opened?

Brian J Druker¹

Affiliations

PMID: 15266089
DOI: 10.1634/theoncologist.9-4-357

Free article

Review

Molecularly targeted therapy: have the floodgates opened?

Brian J Druker. Oncologist. 2004.

Free article

. 2004;9(4):357-60.

doi: 10.1634/theoncologist.9-4-357.

Author

Brian J Druker¹

Affiliation

¹ Howard Hughes Medical Institute, Oregon Health and Science University Cancer Institute, Portland, Oregon 97239, USA. drukerb@ohsu.edu

PMID: 15266089
DOI: 10.1634/theoncologist.9-4-357

No abstract available

PubMed Disclaimer

Similar articles

Another possible mechanism of resistance to STI571.
Knight ZA. Knight ZA. Blood. 2000 Dec 1;96(12):4003-5. Blood. 2000. PMID: 11186275 No abstract available.
Dragons 'round the fleece again: STI571 versus alpha1 acid glycoprotein.
Sausville EA. Sausville EA. J Natl Cancer Inst. 2000 Oct 18;92(20):1626-7. doi: 10.1093/jnci/92.20.1626. J Natl Cancer Inst. 2000. PMID: 11036101 No abstract available.
Cancer stem cells: are we missing the target?
Jones RJ, Matsui WH, Smith BD. Jones RJ, et al. J Natl Cancer Inst. 2004 Apr 21;96(8):583-5. doi: 10.1093/jnci/djh095. J Natl Cancer Inst. 2004. PMID: 15100335 Review. No abstract available.
Imatinib mesylate.
[No authors listed] [No authors listed] Am J Health Syst Pharm. 2001 Dec 1;58(23):2241-2. doi: 10.1093/ajhp/58.23.2241. Am J Health Syst Pharm. 2001. PMID: 11765724 No abstract available.
STI571 (glivec-tm): a new paradigm for the development of innovative therapies in onco-hematology?
Gambacorti C. Gambacorti C. Tumori. 2001 Nov-Dec;87(6):S10-2. Tumori. 2001. PMID: 11989608 Review. No abstract available.

See all similar articles

Cited by

c-Jun-NH2-kinase-1 inhibition leads to antitumor activity in ovarian cancer.
Vivas-Mejia P, Benito JM, Fernandez A, Han HD, Mangala L, Rodriguez-Aguayo C, Chavez-Reyes A, Lin YG, Carey MS, Nick AM, Stone RL, Kim HS, Claret FX, Bornmann W, Hennessy BT, Sanguino A, Peng Z, Sood AK, Lopez-Berestein G. Vivas-Mejia P, et al. Clin Cancer Res. 2010 Jan 1;16(1):184-94. doi: 10.1158/1078-0432.CCR-09-1180. Epub 2009 Dec 22. Clin Cancer Res. 2010. PMID: 20028751 Free PMC article.
Comparison of performance of various tumour response criteria in assessment of regorafenib activity in advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib.
Shinagare AB, Jagannathan JP, Kurra V, Urban T, Manola J, Choy E, Demetri GD, George S, Ramaiya NH. Shinagare AB, et al. Eur J Cancer. 2014 Mar;50(5):981-6. doi: 10.1016/j.ejca.2013.11.037. Epub 2014 Jan 2. Eur J Cancer. 2014. PMID: 24388774 Free PMC article. Clinical Trial.
A new approach for prediction of tumor sensitivity to targeted drugs based on functional data.
Berlow N, Davis LE, Cantor EL, Séguin B, Keller C, Pal R. Berlow N, et al. BMC Bioinformatics. 2013 Jul 29;14:239. doi: 10.1186/1471-2105-14-239. BMC Bioinformatics. 2013. PMID: 23890326 Free PMC article.
Kinase packing defects as drug targets.
Crespo A, Fernández A. Crespo A, et al. Drug Discov Today. 2007 Nov;12(21-22):917-23. doi: 10.1016/j.drudis.2007.09.009. Epub 2007 Oct 30. Drug Discov Today. 2007. PMID: 17993409 Free PMC article. Review.
Advances in development of new tools for the study of phosphohistidine.
Makwana MV, Muimo R, Jackson RF. Makwana MV, et al. Lab Invest. 2018 Mar;98(3):291-303. doi: 10.1038/labinvest.2017.126. Epub 2017 Dec 4. Lab Invest. 2018. PMID: 29200202 Review.

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Silverchair Information Systems
Other Literature Sources
- The Lens - Patent Citations Database